


BL2 LAB UPDATE

ALS TDF is excited to have initiated its first in vivo screening study in the new Biosafety Level 2 (BL2) lab facility. The drug being tested is cyclosporine. Cyclosporine is an immunosuppressive medication used to prevent rejection following solid organ or bone marrow transplantation. It has been investigated as a potential therapeutic for ALS because of its anti-inflammatory properties and its potential to protect mitochondrial membranes. The FDA has recently granted Orphan Drug designation for cyclosporine as a treatment for ALS.

Because of its ability to prevent engraftment rejection, cyclosporine is a drug which will be used regularly in ALS TDF's efforts to test stem cells. Testing the drug not only allows TDF to explore the potential efficacy of a drug that has been in the forefront of the ALS research community for years, but also provides an opportunity to characterize how the drug will behave when used in future stem cell experiments in the BL2 facility.

In January, ALS TDF began the expansion of its laboratory space in order to perform crucial gene therapy and stem cell experiments.

CONTINUED ON P. 8



In Our Lab

ALSGEN discovers drugs that may treat familial ALS:

In October 2004, ALS TDF formally spun off its first biotechnology company, ALSGEN LLC, with the express mission of discovering treatments for SOD1 familial ALS. In its eight months of operation, ALSGEN LLC has discovered 3 classes of brain penetrant small molecules that robustly inhibit the production of the SOD1 protein. The lead compounds of each class are actually FDA approved in keeping with ALS TDF's mission of developing therapies that can be rapidly available to patients. All three classes of drugs were discovered using high throughput screening in a cell based system. ALSGEN is in the process of planning the first trials based on these molecules. The strategy of inhibiting SOD1 production as a therapy was put to the test recently by Ralph et. al. who demonstrate an 80% extension in the lifespan of the mouse using a virally delivered SOD1 knockdown strategy. The success of this

CONTINUED ON P. 3

Letter from the Director

In the fall of 2004, ALS TDF helped in the formation of ALSGEN, a Princeton, New Jersey-based biopharmaceutical company working to develop both drugs and siRNA targeted at reducing SOD1, the protein that causes genetic ALS. Our front page story details the progress ALSGEN has made toward discovering drugs that may treat familial ALS. ALSGEN is led by Dr. Dan Benjamin, a drug development expert with 20+ years of industry experience and a proven record of success, running high throughput screening operations for companies such as J&J and FMC, and has been the recipient of 15 NIH grants as a professor at Rutgers.

ALS TDF was formed to find treatments for today's ALS patients. Our research laboratory is dedicated to filling a translational research gap between academic exploration and treating patients. We perform the critical validation of new therapies and then help speed those with promise to the clinic. ALS TDF also manages the discovery and development of new targets for ALS. The task of actually developing a drug is a very complicated professional endeavor that involves chemistry, discovery, and a variety of skills that almost exclusively exist at biopharmaceutical companies.

ALS TDF has worked with over 40

companies in evaluating and developing ALS therapies and our current program involves dozens of active joint development programs. These programs are our most promising potential therapies for ALS patients because the companies provide key leadership, drug chemistry and potential trial funding support.

The rapid formation and development success of ALSGEN is a significant validation of ALS TDF's entire approach. To succeed for the patients we work for we must make research of ALS possible and profitable for companies. ALS TDF's partnership with ALSGEN makes possible a company that would not be able to exist without our research program and it is already bearing fruit with 3 classes of drugs and initial experiments that show siRNA can reduce SOD1 levels. I regard this as a model of how future development can work.

It is you, the people that support ALS TDF that have made this success possible.



James Allen Heywood
d'Arbeloff Founding Director



» James Allen Heywood.

FOR MORE INFORMATION:

Research & Development
Nancy Kelly
nkelly@als.net

Patient Resources
Mary Beth Parks, R.N.
mbparks@als.net

Funding the Research
Molly Brady
mbrady@als.net

Communications
Brigitte LaMarche
blamarche@als.net

important proof of principle experiment underscores the importance of bringing these therapies to patients rapidly.

ALSGEN has also developed a completely novel siRNA construct. siRNA is a subset of RNAi, the technology that tricks the cell into destroying the RNA for a particular protein thus preventing the creation of the protein. siRNA has the added benefit of escaping an immune response whereas RNAi frequently provokes an interferon response. ALSGEN's siRNA can knock down SOD1 RNA when delivered intrathecally using ALS TDF's new murine IT infusion system. This siRNA is very potent, it can lower SOD1 levels by 50% (EC50) at a concentration of less than 50nM and appears to work in the mouse when delivered completely naked. (i.e. when used as a drug, no virus/gene therapy needed).

ALSGEN is led by chief scientific officer Daniel Benjamin Ph.D., a molecular neuropharmacologist with expertise in high throughput screening and siRNA/Antisense design in collaboration with ALS TDF's R&D team led by Sean Scott. ALSGEN has been remarkably productive with a limited initial investment. An unexpected benefit of ALSGEN's discoveries is their potential for application in sporadic ALS. This is an avenue under aggressive pursuit at ALS TDF.

Background:

It's no secret that ALS TDF's research efforts over the last four years have been

directed predominantly toward finding a treatment for sporadic ALS. Over this time, it has become apparent to our researchers, and the community as a whole, that the SOD1 familial form of the disease might be treatable in the very near term by simply lowering the quantity of SOD1 protein in the CNS. This belief is based on the observation that less of the SOD1 protein produces later onset and longer life-spans in the various SOD1 mouse models.

To date, two companies have announced that they are developing technology aimed at inhibiting the production of the SOD1 protein using novel gene knockdown strategies. Isis Pharmaceutical in Carlsbad, California is pursuing the development of an antisense to SOD1, while CytRx in Los Angeles is developing a virally delivered RNAi. Both technologies are extremely exciting, however, they will need to undergo a full, multi-year development cycle because of their novelty.

Because many of ALS TDF's constituents either have, or are at risk of developing, the SOD1 familial form of the disease, the R&D team has been aggressively pursuing an alternative strategy for inhibiting the production of SOD1. Taking advantage of private equity financing provided for this express purpose, ALS TDF formed ALSGEN LLC, a biotechnology company whose mission is to develop treatments for familial form of the disease.

ALSGEN brought on board as its chief

scientific officer and co-founder, Daniel Benjamin, Ph.D. a sought after drug hunter with an impressive list of accomplishments in pharmaceutical drug discovery.

Why would a non-profit create a private company?

ALS TDF has always existed to perform the tasks that couldn't or wouldn't be done by industry, thereby lowering the risk for companies and encouraging them to get involved in research. ALS TDF has always believed that big companies will be required to invest the large dollars required to take a drug candidate through the trial process. This is the reason ALS TDF has started more than 40 corporate collaborations over the last 5 years. In the SOD1 familial ALS, the time was right to shift the burden to the private sector and take advantage of funding that would not have been available to ALS TDF otherwise. This practice has been successfully employed by the Cystic Fibrosis Foundation, for example, who has invested in or spun off no less than ten biotechnology companies that are focused on the CF foundation's priorities.

Inquiries about ALSGEN LLC or the SOD1 technology may be directed to Nancy Kelly at nkelly@als.net.

FOR MORE INFORMATION:

Visit www.als.net and click on "In Our Lab" to view our drug pipeline and more.

R&D Update

New Leads in Screening:

ELMIRON/PENTOSAN

Elmiron is FDA approved for the relief of pain and discomfort associated with interstitial cystitis. It's been used since the 1960s in Europe as an anti-coagulant and is similar to heparin though much less effective. This drug has anti-inflammatory and anti-protein aggregation properties. Two years ago the foundation heard the story of a young variant Creutzfeldt-Jacob Disease (vCJD) (the human form of mad cow disease) patient named Johnathan Simms in the UK whose family and doctor were fighting a legal battle to

get the approval to test pentosan for Johnathan on a compassionate-use basis. The courts eventually allowed this therapy to go forward. Prior to taking pentosan Johnathan was considered terminally ill. Today, two years after initiating pentosan treatment, his condition is stable. On average, patients diagnosed with vCJD survive only 14 months. Johnathan is the only vCJD patient known to survive with this disease for three years and counting. Dr. Stephen Dealler a member of the team of experts working on Johnathan's case has treated 12 other vCJD patients with pentosan. According to Dealler half of those

treated have continued progressing without improvement while the condition of the other six has stabilized. vCJD and ALS are both what are called protein conformational diseases where the disease causing protein aggregates and throws cellular homeostasis off balance. Pentosan inhibits protein aggregation in alzheimer's and diabetes models and it is theorized to do so in vCJD. ALS TDF believes that pentosan may be beneficial in ALS as well, because one of the known disease-causing agents in ALS is aggregating proteins. Pentosan is also a known complement C inhibitor that acts as an anti-inflammatory. ALS TDF tested

pentosan in the G93A mouse model. The intra-cerebral ventricular (ICV) delivery caused problems with generating a clean study because we lost a number of mice when we changed the ICV pumps half way through the study. We plan on repeating this study using our new intrathecal (direct to mouse spine) delivery method. This next efficacy study is set to begin this month.

THREE SMALL MOLECULE SOD1 PROTEIN INHIBITORS


ALSGEN, a spinoff of ALS TDF [see newsletter cover], has tested approximately 2,500 small molecules out of a library of FDA approved drugs and novel compounds in a cellular assay system with the goal of knocking down the familial ALS causing mutant SOD1 protein. The screen yielded three "hits" all of which inhibit the mSOD1 protein. The lifespan of the G93A mouse is directly proportional to the amount of mSOD1 protein produced. Decreasing mSOD1 expression in the mice and theoretically in familial SOD1 patients should arrest progression of ALS symptoms and greatly extend function and lifespan. One of the small molecules discovered by the screen may have a mechanism that could affect the sporadic form of the disease as well. Pilot studies are ongoing

in our lab and full efficacy studies will follow once dosing and tolerability in mice is worked out.

CYCLOSPORINE

Cyclosporine is an immunosuppressive agent FDA approved to prevent organ or other tissue transplant rejection. It's also used to fight autoimmune conditions, like type I diabetes, psoriasis, rheumatoid arthritis, inflammatory bowel disease and some neuropathies.

Dr. Stan Appel, an ALS clinician and researcher, studied cyclosporine in an ALS clinical trial in 1988. The results of the trial showed no change in the rate of monthly progression in the patients receiving the drug. However, Dr. Appel noted that it showed mild benefit for men who were in the early stages of disease progression. The fact that cyclosporine does not penetrate the blood brain barrier and was given peripherally in the human study but managed to show some improvement was intriguing. ALS TDF felt the need to run cyclosporine in the mice but had other more readily brain penetrant drugs



ahead of cyclosporine in the drug testing queue. However, recent research from Karlsson et al. and Kirkinetzos et al. suggests that cyclosporine may increase survival in the mouse, perhaps by mitochondrial pathway which is one of the main suspects in ALS disease pathogenesis. Mitochondria are cellular organelles that generate cellular energy. Alterations in the functionality of these cellular powerhouses can result in the initiation of

cell death programs that contribute to neurodegenerative diseases like ALS. A key process involved in cell death [in this cascade] is the increase in permeability of the

outer and inner mitochondrial membrane. The formation of the mitochondrial permeability transition pore or MPTP can trigger the release of cell death initiating factors from the mitochondria themselves as well as loss of Adenosine triphosphate (ATP), which performs essential roles in the cell such as providing energy for most of the energy-consuming activities of the cell, is used in the synthesis of RNA and after conversion to and regulates many biochemical pathways. The

CONTINUED ON P. 6

R&D UPDATE CONTINUED FROM PAGE 5 ...


factors that are released from the mitochondria are cytochrome c, apoptosis inducing factor (AIF) and some caspases which are enzymes that break down proteins during cell death. Cyclosporine is a drug that could interfere with MPTP and abate cellular injury. Our lab is planning on running cyclosporine first peripherally and then for comparison delivered directly to the central nervous system via the intrathecal catheter system we've developed. The first of these studies in mice is scheduled to begin shortly in our lab.

Thanks

The staff at the ALS Therapy Development Foundation wishes to thank Becton, Dickinson and Company, a medical technology company in Franklin Lakes, New Jersey that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public, for its enormous generosity in donating much-needed scientific supplies to the ALS TDF laboratory. The lab continues to benefit from the donation of tuberculin syringes, microtainer tubes, needles, pipettes, microplates and Falcon Lab plastic disposable supplies that are used daily to formulate compounds, administer test drugs and collect tissues for analysis and routine molecular biology and biochemistry.

A special thank you goes to those at Becton, Dickinson who made this donation possible: David M. Fortunato, Senior Intellectual Property Counsel; David Highet, Vice President and Chief Patent Counsel and Jennifer Farrington, Community Relations.

ALS TDF continues to need supplies and equipment to assist our scientific staff with their training and research and welcomes such donations to assist in our research program. Any donation large or small is appreciated. If you are interested in making a donation of supplies or equipment, please contact Anya Goodridge at (617) 441-7244.



"Hey, no problem!"

© The New Yorker Collection from cartoonbank.com. All Rights Reserved.

ALS TDF Welcomes our Director of Gene Expression Core



Gerard "Jerry" De Zutter, Ph.D. joined the ALS TDF Research and Development team in March, 2005 as the Director of Gene Expression Core, heading up the Quantitative Gene Expression Core program. Jerry comes to ALS TDF with over five years of biotechnology research experience, most recently with Wyeth Discovery Research. While at Wyeth, his work focused on uncovering new therapeutic targets in inflammatory diseases. He received his doctorate from the University of Massachusetts/UMass Medical Center in biochemistry and molecular biology, specializing in neurodegenerative disease and signal transduction research.



A Massachusetts native, Jerry is an incredibly accomplished athlete, competing in alpine skiing, marathons and triathlons. A ten-time finisher of the Boston Marathon (eight consecutive races), Jerry can often be seen running around Cambridge when not in the lab. He also participates in "ultramarathons," distances beyond the standard 26.2 mile race, and once completed 114 miles in 24 hours at the Around the Lake 24hr race in Wakefield, MA.

Jerry is extremely excited to be a part of the team at ALS TDF and says, "Working for this organization provides me the personally satisfying experiences of both benefiting from patient insight as well as seeing how our research efforts directly impact ALS. Scientifically, the focused yet agile nature of our group challenges and combines the intellect and skills gained from my academic and industrial experiences and I eagerly anticipate the road ahead for our program."

» Top: Jerry De Zutter, Ph.D., ALS TDF's new Director of Gene Expression Core.

Bottom: Running a race.

BL2 LAB UPDATE CONTINUED FROM PAGE 1...

While we continue our dedication to the pursuit of drug or small molecule therapies, we are adding gene therapy and stem cell tests to our comprehensive testing program because we believe they will play an important role in developing a treatment or restorative regimen for ALS patients.

With the lab expansion completed and the first in vivo experiment currently running in the new facility, ALS TDF is now poised to explore even more avenues toward potential ALS therapeutics.

ALS TDF runs the world's largest animal drug testing program for ALS. Our existing lab houses 800 mice at any given time, with as many as 8-12 full efficacy studies running concurrently. We are thrilled that the new facility and expanded testing program will help us find an even faster cure.

A Cure is Coming!



» Top: Participants line the Lexington Battle Green.

Bottom: from the left, Jerry De Zutter, Ph.D., ALS TDF's new Director of Gene Expression Core with Joan Melanson of Ken Melanson's Quest for a Cure and Christopher Pendergast, Founder and President of Ride for Life.

On Saturday, April 16, 2005,

over 75 friends of ALS TDF and Ride for Life set out from the Lexington Battle Green to rewrite history. A Cure is Coming! – A 12-mile ALS Awareness Walk was inspired by Christopher Pendergast and his annual Ride for Life effort in New York. The group of ALS patients in their wheelchairs and friends and family members on foot re-traced Paul Revere's historic ride in reverse, traveling from Lexington into Boston and raising awareness along the way. From the starting point in Lexington, participants were led by members of the Lexington Minutemen in Revolutionary War dress who fired their muskets and readied the troops for battle. After a brief rest stop in Arlington and a lunch break at Medford City Hall, the group rode/walked into Boston along the Freedom Trail proclaiming, "It's Time for A Cure!" A reception and candlelight vigil at the Old North Church remembered loved ones who fought ALS and honored all of those currently battling ALS today. Speakers included Kim Julian, Founding Director of Driving 4 Life and Christopher Pendergast, Founder and President of Ride for Life. The First Annual A Cure is Coming! raised over \$10,000 for the Research Center at ALS TDF and brought ALS awareness to the Greater Boston Community.

FOR MORE INFORMATION:

Contact Jamie Manganello
jmanganello@als.net

ALS TDF LEADERSHIP AWARDS

This year we will begin a tradition of honoring the people who battle ALS every-day. The awards are named after some of those who inspire our work, support our mission and fuel the spirit of our fight. We ask you to consider nominating a friend or family member to receive one of these prestigious awards. These people are patients, caregivers, families, friends, and entire communities focused on a cure.

Fran Delaney Challenge & Respect Award

The recipient of this award continually challenges ALS science and research and helps drive new fundraising initiatives to help promote the mission of ALS TDF.

Mary Lou Krauseneck Courage & Love Award

This person is a model of strength, courage and love in the community and inspires people to keep a passion for life strong in the battle against ALS.

Stephen Milne Adventurous Spirit Award

This award is presented to a person in the ALS community who bravely explores new ground in combating ALS within their own community by searching for innovative ways to raise funds and awareness.

Stephen Heywood Patients Today Award

This award is given to a selfless person who is the inspiration that drives others to ask the questions, and ensures that the focus of ALS research remains on Patients Today.

Nominations are due August 1, 2005 and awards will be announced at the Leadership Summit in Cambridge, MA on August 25, 2005.

For further descriptions and to nominate someone for an Award: Visit www.als.net or call Molly Brady at 617.441.7249 for a nomination form.



• Accelerating a Cure – Inspired by Passion



» Mary Lou Krauseneck (center) with family and friends.

The amazing community behind the Mary Lou Krauseneck Fund

has surpassed their \$1,000,000 fundraising goal for ALS TDF. This didn't happen without the commitment and devotion of literally hundreds of people coming together to plan multiple events over the past four years. Mary Lou is an inspiration and her passion for life fuels the masses to change the

scope of research in the face of a devastating disease.

The "A Passion for Life" committee formed shortly after Mary Lou's diagnosis in June of 2000. Since its start, the committee has created and sold a cookbook, held four "A Passion for Life" Benefits and Celebrations with over 600 people in attendance each year, and have kicked off a "Walk with Passion"

which has become an annual 2 mile awareness walk.

"When I walk into the room at the A Passion for Life Benefit and Celebration, I am literally moved by the outpouring of love and the energy of the committee", said James Heywood. "Each year I look forward to attending this event to recharge my batteries to fight this disease."

The committee is headed by Bernadette Cooper and Amy Whipple, Mary Lou's sister and niece. This committee is comprised of over sixty people who know Mary Lou and felt the need to get involved in the shared mission of accelerating drug discovery efforts to bring about a cure for ALS.

Due to their efforts, we have named the Passion Drug Delivery Program in Mary Lou's honor. During the 2005 benefit, Fernando Vieira, a researcher at ALS TDF, was recognized for his contributions to the Passion Drug Delivery Program. This is the much acclaimed drug delivery program involving catheterization of the mouse allowing for higher concentrations of drugs to reach the spinal cord.

Mary Lou Krauseneck is a testament to hope, faith, and love in the face of any challenge. Her passion has inspired an entire community and has helped ALS TDF further our mission of accelerating a cure for ALS.



» Left: Ann Terice, pictured with husband Howard, arranges the more than 400 baskets of donated treasures into unique gifts for each lucky auction winner.

Right: Bernadette Cooper, Mary Lou's sister.

“When I walk into the room at the A Passion for Life Benefit and Celebration, I am literally moved by the outpouring of love and the energy of the committee. Each year I look forward to attending this event to recharge my batteries to fight this disease.”

James Heywood

• Excerpts from “The Powerful Play Goes On”



» Scott, Kirsten and Eva Stafne.

Scott Stafne keeps an online journal of his thoughts. Here is a short excerpt that we'd like to share with you.

Do you believe in miracles?

I had no idea. I had no idea. For all the time I've spent imagining what it would be like to become a father, I realized that you simply can't know until it happens. Watching my little girl being born was a dream come true, easily the most memorable moment of my life. I am so overwhelmed and awed by our little girl. Her existence and my related feelings and emotions simply cannot be explained within my mind, with science, with biology. I am just totally and completely engulfed in love for my wife and daughter. It seems as though my reason for being has finally been revealed to me. Like all

of my life to this point has been in preparation for fatherhood.

While I've been able to primarily focus on all the good stuff lately, the reality of my situation still raises its ugly head from time to time. While at the hospital, as I was rocking with my daughter and seemingly staring at her for hours, I was suddenly struck by an intense, guttural terror that I might not be around for her. I've had similar feelings before, but never so acute. It seems the old saying is true, the higher the highs, the lower the lows. Thankfully those feelings have come less often and I've been able to focus on spending time with my girls. If anything, my determination to fight this illness with every ounce of strength I have grows every time I look at her. Quite often I don't want to sleep. I want to experience every possible second with her, be there for her, keep her safe.

Life is indeed a miracle. My daughter has helped me recognize that fact in a very real way. Appropriate then that we named her Eva, derived from Eve, the penultimate name for life. She represents everything that is good in the world to me. Her arrival has helped keep my hope for another miracle alive. The hope for a cure. But until that day, I will simply enjoy being her dad, holding her, watching her sleep, staring into her eyes, and telling her how much I love her.

Scott and Kirsten attended ALS 101 in Chicago this year and have been raising funds and awareness for ALS TDF ever since. Read more from Scott's Blog and visit their website at www.stafnes.com.

Pee Wee Team Honors Coach



It is a ritual that goes back to the beginning of sports.

At the end of the season there are the player awards and the coach gifts. But what do you get the coach who has everything? A coach that owns a chain of sporting goods stores hardly needs a gift certificate to one. This is the annual struggle faced by the Hanover Wild Pee-Wee ice hockey team of Hanover, New Hampshire.

The coach, Scott Peters of Golf & Ski Warehouse, is a sports enthusiast that is difficult to buy for. But the answer to this riddle was in front of their eyes all season long. "I had been wear-

ing, throughout the season, the lime green Driving 4 Life wristband. Before one of our practices, one of the kids said, "Hey coach, what is that bracelet for?" remembers Coach Peters. "I proceeded to tell him about my best friend Jeff Julian and how he died recently of ALS. It obviously struck my little guys because they all wanted bracelets after hearing the story."

Kids remember things. They also care about what their teachers and role models care about. To this group of eleven and twelve year olds, the message was loud and clear according to team captain, Patrick Luan, "Jeff Julian meant a lot to Coach Peters. Everyone

on the team thought that this would be better than any gift certificate. It was a unanimous decision that everyone thought would be more meaningful."

At the end of the season the Hanover Wild presented their coach with a check for more than \$300 to be donated to Driving 4 Life in his name. "It was the best gift they could have given me. It is about building awareness and education about ALS," said Peters, "as well as keeping Jeff's dream to find a cure alive. It's pretty cool that these kids got it and wanted to make a difference."



Save the date!

DRIVING 4 LIFE INVITATIONAL 2005
September 12th, 2005
Trump National Golf Club
Bedminster, NJ

Corporate Sponsorships
Foursome Packages Available!
617-441-7200

Finally, a wristband
for the golfer.



Two Years, Two Million Raised!

Now filling new orders for this quick and easy fundraiser. Sell or give as gifts to family members, friends and colleagues. All proceeds go to Driving 4 Life and ALS TDF.

50 wristbands for only \$100.

Call Rob @ 617-441-7295 for more information.

CAMPAIGN UPDATE

Driving 4 Life gained momentum this year and a slew of events are planned for the summer and fall stretching from coast to coast.

A number of great tournaments were held over the first half of the year raising more than \$250,000 for ALS research. These events were held from Key West, Florida to Prescott, Arizona to Newbury, New Hampshire, bringing Driving 4 Life to new locales and teaching people about ALS and how to get involved in our campaign to find a cure.

The 2nd Annual Driving 4 Life Invitational will return to Trump National in Bedminster, New Jersey, September 12th. Foursomes and sponsorships are still available.

The Driving 4 Life Memorial Wristband continues to be a popular item and after quickly going through the initial supply we are again filling orders. Wristbands come in boxes of 50 and are a quick and easy fundraiser. Order a box or two to sell at your local golf club, social organization or to friends and family.

It is easier than ever to begin planning your own Driving 4 Life charity golf tournament, teach-a-thon, or other fundraiser. Our dedicated team of event professionals can help you every step of the way. Order your new and improved event manual and tool-kit and start learning how easy it is to make a big difference.

FOR MORE INFORMATION:

Support Driving 4 Life by visiting:
www.driving4life.org



» Volunteers hanging a banner at the 1st Annual Dick Sanderson Driving 4 Life Golf Tournament in Davidson, North Carolina.



» The Ellis Family at the 2nd Annual Larry Ellis Driving 4 Life event in Crofton, Maryland.

It has never been easier to put together your own Driving 4 Life fundraiser. Join the campaign today and learn "The many ways you can fundraise", such as:

- Golf Tournaments
- Casino Nights
- Driving Range Events
- Teach-A-Thons
- Letter writing campaigns
- Embroidered hat and wristband sales

Dear Friends,

It was a rollercoaster ride from the beginning. We threw together some information, wrote a few letters, Tom and Bruce did a PSA that was shown during the US OPEN and money started to come in. People started to pay a lot of attention to Bruce and Jeff and began asking important questions. Why isn't there a treatment for ALS? Why don't major pharmaceutical companies invest more in ALS research? Simply, why hasn't more been done?

Driving 4 Life was created to answer those questions by raising money and awareness through the game that Jeff and Bruce loved dearly: golf. To date, the campaign has raised nearly \$2 million which significantly supports and advances aggressive research at ALS TDF to slow, arrest, and cure ALS.

You all are the reason my husband and Bruce are remembered. Your continued support of the Driving 4 Life campaign and its programs will allow the Research Center at ALS TDF to remain the world's leading ALS therapy discovery center, keeping Jeff and Bruce's legacy alive. We are off to a great start this year, but we need your help to meet our increased fundraising goal.

Thank you for the past two years,

Kim Julian
Founding Director, Driving 4 Life

FOR MORE INFORMATION:

Contact Kim Julian
kjulian@als.net

Events

(JULY - SEPTEMBER)

+ July 12th

Stephen Milne Society,
Erie Branch
Golf Tournament
Kahkwa Golf Club, Erie, PA
Contact: Molly Brady
mbrady@als.net

+ July 15th-17th

Tri State Trek
Newton, MA to White Plains, NY
Contact: Mat Mendel
www.tristatetrek.com

+ August 6th

Teach to Fight ALS
Hamlet Golf and Country Club,
Commack, NY
Contact: Rob Goldstein
rgoldstein@als.net

+ August 12th

Golf 4 ALS
Hampden Country Club,
Hampden, MA
Contact: Walt Tucker
www.golf4als.com

+ August 13th

Driving 4 Life Charity
Golf Tournament
Woodbine Bend Country Club,
Stockton, IL
Contact: Lou Kobbs
lkobbs@als.net

+ September 10th

The 4th Annual Jim Raspanti
ALS Golf Outing
Frosty Valley Golf Links,
Upper St. Clair, PA
Contact: Gerry Simon
gsimon@ugtic.com

+ September 11th

Annual Cliff Walk for ALS
Buzzards Bay Recreational Area,
Buzzards Bay, MA
Contact: www.alsfamily.org

+ September 11th

2nd Annual "A Passion for Life"
Walk
Stonycreek Metropark,
Shelby Township, MI
Contact: Amy Whipple
anwhipple@comcast.net

+ September 12th

Driving 4 Life Invitational
Trump National Golf Club,
Bedminster, NJ
Contact: Rob Goldstein
rgoldstein@als.net

+ September 17th

The 3rd Annual Night of
Rhythm and Hope
Sheraton at Station Square,
Pittsburgh, PA
Contact: Jill Theodoss
jtheodoss@als.net

+ September 18th

The 4th Annual Jeff Julian
Tournament
Ledgestone Country Club,
Branson, MO
Contact: Jeff Walster
866-334-4477

+ September 20th

First Annual Brown & Brown
Driving 4 Life Tournament
Southers Marsh Golf Club,
North Plymouth, MA
Contact: Rob Goldstein
rgoldstein@als.net